Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia
Autor: | Samantha L. Savage, Dongqing Yan, Michael W. Deininger, Matthew S. Zabriskie, Brian J. Druker, Thomas O'Hare, Christopher A. Eide, Anthony D. Pomicter, Nadeem A. Vellore |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2015 |
Předmět: |
0301 basic medicine
Cancer Research medicine.medical_specialty Indazoles Axitinib Fusion Proteins bcr-abl Pharmacology 03 medical and health sciences Bcr abl1 0302 clinical medicine hemic and lymphatic diseases Internal medicine Leukemia Myelogenous Chronic BCR-ABL Positive mental disorders medicine Humans Letter to the Editor Protein Kinase Inhibitors Hematology business.industry Imidazoles medicine.disease 3. Good health Leukemia 030104 developmental biology Oncology 030220 oncology & carcinogenesis Mutation Cancer research business medicine.drug |
Zdroj: | Leukemia |
ISSN: | 1476-5551 0887-6924 |
Popis: | Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia |
Databáze: | OpenAIRE |
Externí odkaz: |